The Drug-Induced Respiratory Disease Website
Hypersensitivity and infusion reactions. May mimic systemic vasculitis (PMID 30746133). See also under 'Anaphylaxis' (Xf). Hypersensitivity reactions include the rapid development of malaise, cough, dyspnea, wheezing-bronchospasm, cutaneous rash, itching and pruritus. These symptoms may annunciate the onset of anaphylaxis (see Xf) especially if the drug is continued or the patient is inadvertenly rechallenged with the drug. Desensitization can be offered (PMID 26895621), so that patients can receive full treatment courses and need not be switched to an alternative, potentially more toxic or inferior therapy. See PMID 12634903, 12721396, 22149339, 22987983. Skin manifestations at PMID 24820798
Publications
[Etoposide desensitization. A case report].
Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2010 Jan-Feb;57;33-6 — 2010 Jan-Feb — 33-6
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
British journal of cancer 2002 Jan 07;86;12-3 — 2002 Jan 07 — 12-3
Hypersensitivity reactions to etoposide. A report of three cases and review of the literature.
American journal of clinical oncology 1994 Oct;17;387-9 — 1994 Oct — 387-9
Hypersensitivity reactions induced by etoposide.
Cancer treatment reports 1984 Jul-Aug;68;959-61 — 1984 Jul-Aug — 959-61
Two cases of suspected immunologic-based hypersensitivity reactions to etoposide therapy.
The Annals of pharmacotherapy 1992 Oct;26;1227-30 — 1992 Oct — 1227-30